179 related articles for article (PubMed ID: 34813051)
1. Penpulimab: First Approval.
Dhillon S
Drugs; 2021 Dec; 81(18):2159-2166. PubMed ID: 34813051
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune hemolytic anemia in patients with relapsed Hodgkin's lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1.
Tao Y; Han J; Li Y
Invest New Drugs; 2022 Aug; 40(4):854-857. PubMed ID: 35503192
[TBL] [Abstract][Full Text] [Related]
3. Zimberelimab: First Approval.
Markham A
Drugs; 2021 Nov; 81(17):2063-2068. PubMed ID: 34709602
[TBL] [Abstract][Full Text] [Related]
4. Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell death-1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105-204).
Zheng Y; Zhu J; Xiong J; Jiang O; Wang H; Xie Y; Zhou Y; Xu N
Cancer; 2024 Jun; 130(12):2180-2190. PubMed ID: 38412283
[TBL] [Abstract][Full Text] [Related]
5. Tislelizumab: First Approval.
Lee A; Keam SJ
Drugs; 2020 Apr; 80(6):617-624. PubMed ID: 32185681
[TBL] [Abstract][Full Text] [Related]
6. Sintilimab: First Global Approval.
Hoy SM
Drugs; 2019 Feb; 79(3):341-346. PubMed ID: 30742278
[TBL] [Abstract][Full Text] [Related]
7. Camrelizumab: First Global Approval.
Markham A; Keam SJ
Drugs; 2019 Aug; 79(12):1355-1361. PubMed ID: 31313098
[TBL] [Abstract][Full Text] [Related]
8. Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1.
Song H; Liu X; Jiang L; Li F; Zhang R; Wang P
Recent Pat Anticancer Drug Discov; 2021; 16(3):312-332. PubMed ID: 33563158
[TBL] [Abstract][Full Text] [Related]
9. Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers.
Zheng Y; Mislang ARA; Coward J; Cosman R; Cooper A; Underhill C; Zhu J; Xiong J; Jiang O; Wang H; Xie Y; Zhou Y; Jin X; Li B; Wang ZM; Kwek KY; Xia D; Xia Y; Xu N
Cancer Immunol Immunother; 2022 Oct; 71(10):2371-2379. PubMed ID: 35165764
[TBL] [Abstract][Full Text] [Related]
10. Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events.
Huang Z; Pang X; Zhong T; Qu T; Chen N; Ma S; He X; Xia D; Wang M; Xia M; Li B
Front Immunol; 2022; 13():924542. PubMed ID: 35833116
[TBL] [Abstract][Full Text] [Related]
11. Cadonilimab: First Approval.
Keam SJ
Drugs; 2022 Aug; 82(12):1333-1339. PubMed ID: 35986837
[TBL] [Abstract][Full Text] [Related]
12. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
Liu Y; Wang C; Li X; Dong L; Yang Q; Chen M; Shi F; Brock M; Liu M; Mei Q; Liu J; Nie J; Han W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820822
[TBL] [Abstract][Full Text] [Related]
13. Sugemalimab: First Approval.
Dhillon S; Duggan S
Drugs; 2022 Apr; 82(5):593-599. PubMed ID: 35298827
[TBL] [Abstract][Full Text] [Related]
14. Retifanlimab: First Approval.
Kang C
Drugs; 2023 Jun; 83(8):731-737. PubMed ID: 37184754
[TBL] [Abstract][Full Text] [Related]
15. Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201).
Song Y; Zhou K; Jin C; Qian Z; Hou M; Fan L; Li F; Ding K; Zhou H; Li X; Chen B; Sun X; Song X; Jiang M; Zhang Q; Liu L; Yu G; Hu Y; Zhao Z; Liu L; Xue H; Luo J; He B; Jin X; Zhao M; Li B; Xia Y; Zhu J
Front Oncol; 2022; 12():925236. PubMed ID: 35875118
[TBL] [Abstract][Full Text] [Related]
16. Tafasitamab: First Approval.
Hoy SM
Drugs; 2020 Nov; 80(16):1731-1737. PubMed ID: 32946059
[TBL] [Abstract][Full Text] [Related]
17. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.
Dada R
Ann Hematol; 2018 Apr; 97(4):555-561. PubMed ID: 29322203
[TBL] [Abstract][Full Text] [Related]
18. Serplulimab: First Approval.
Lee A
Drugs; 2022 Jul; 82(10):1137-1141. PubMed ID: 35796953
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
20. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
Sukari A; Nagasaka M; Alhasan R; Patel D; Wozniak A; Ramchandren R; Vaishampayan U; Weise A; Flaherty L; Jang H; Kim S; Gadgeel S
Anticancer Res; 2019 Feb; 39(2):781-790. PubMed ID: 30711957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]